Skip to Content

Effect of Siponimod on Cognition in MS Patients Explored

THURSDAY, Dec. 17, 2020 -- Some cognitive tests but not others suggest siponimod may speed cognitive processing in patients with secondary progressive (SP) multiple sclerosis (MS), according to a study published online Dec. 16 in Neurology.

Ralph H.B. Benedict, Ph.D., from the University at Buffalo in New York, and colleagues conducted secondary analyses of data from a double-blind, phase 3 trial involving 1,651 SPMS patients randomly assigned to receive either siponimod or placebo in a 2:1 ratio. The Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT), and Brief Visuospatial Memory Test-Revised (BVMT-R) were used to assess cognitive function.

The researchers found that at months 12, 18, and 24, the between-group differences in mean change from baseline in SDMT scores were significantly better for siponimod-treated versus placebo-treated patients (difference, 1.08, 1.23, and 2.30, respectively). The risk for having a 4-point sustained decrease in SDMT score was significantly lower for siponimod-treated patients (hazard ratio, 0.79), while they had a higher chance of having a 4-point sustained increase in the SDMT score (hazard ratio, 1.28). There was no significant between-group difference observed in the PASAT or BVMT-R scores.

"We are impressed to see that siponimod may improve cognitive processing speed in people with MS; however, more research is needed to confirm our results," Benedict said in a statement. "Because we did not see changes on two other cognitive tests, more research should further examine how siponimod affects scores on a broader array of thinking and memory tests."

Several authors disclosed financial ties to biopharmaceutical companies, including Novartis, which manufactures siponimod and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Posted: December 2020

Read this next

Stem Cell Transplant May Slow Disability in Multiple Sclerosis

THURSDAY, Jan. 21, 2021 -- For patients with multiple sclerosis (MS), autologous hematopoietic stem cell transplantation (aHSCT) may prevent worsening of disability, according to...

Pregnancy Outcomes Examined for Women With Multiple Sclerosis

WEDNESDAY, Jan. 13, 2021 -- Women with pregnancy after versus before a multiple sclerosis (MS) diagnosis have fewer children and at an older age, according to a study published in...

Over Half of Adults With MS Report Some Form of Caregiver Abuse

MONDAY, Nov. 2, 2020 -- More than 50 percent of adults with multiple sclerosis (MS) report some form of caregiver abuse, according to a study published in the November issue of...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.